Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Pastimes : Clown-Free Zone... sorry, no clowns allowed -- Ignore unavailable to you. Want to Upgrade?

To: Terry Maloney who wrote (313042)	10/2/2005 7:34:02 PM
From: Elroy Jetson	Respond to of 436258

The Tamiflu and Relenza situation with Bird Flu is similar to the situation with HIV. All drugs in a certain class target the same enzyme. But when a mutant virus emerges to escape the shape of one drug, they typically become less fit and less virulent (This is because wild-virus has emerged as the most fit). The mutant virus is also likely to be blocked by a drug with a different molecule which has a different shape. The development process and thus the molecules of Relenza and Tamiflu are quite different. This minimizes the likelihood of cross-resistance. Me-too drug development in HIV led to more drug cross-resistance than you might otherwise expect. .